《基孔肯雅热诊疗方案（2025年版）》发布；脑机接口再传消息

Group 1: Healthcare Policy and Regulations - The National Health Commission issued the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)" to improve medical treatment standards for Chikungunya fever [1] - The National Medical Insurance Administration released the "Basic Medical Insurance Fund Instant Settlement Handling Procedures (Trial)" to streamline the settlement process for medical expenses [2] - The National Medical Insurance Administration established a new pricing mechanism for innovative drugs and medical devices, including specific pricing for brain-computer interface technologies [3] Group 2: Drug and Vaccine Approvals - Hengrui Medicine's subsidiaries received clinical trial approval for three drug candidates, including SHR-8068, a fully human anti-CTLA-4 monoclonal antibody [4] - Laika Pharmaceuticals announced FDA approval for clinical trials of LAE103, a monoclonal antibody targeting ActRIIB for muscle-related diseases [5] - Beijing Kexing's combined hepatitis A and B vaccine received re-registration approval, becoming the only approved combined vaccine in China [7] Group 3: Clinical Trial Results - Yahui Pharmaceuticals reported positive preliminary results from the Phase Ib clinical trial of APL-1401 for moderate to severe active ulcerative colitis [8] Group 4: Financial Performance - Hendi Pharmaceuticals reported a 72.92% year-on-year decrease in net profit for the first half of the year, with revenue of 235 million yuan, down 2.93% [10] Group 5: Mergers and Acquisitions - Lidman Biochemical is planning to acquire up to 70% of Xiangrui Biological's shares, a company focused on in vitro diagnostic reagents and human vaccines [11] Group 6: Industry Developments - Yuanda Pharmaceutical secured exclusive agency rights for the medical-grade Ge-68/Ga-68 generator in China, enhancing its position in the nuclear medicine sector [13] - Shenyang Biological signed a cooperation agreement with Lanzhou Veterinary Research Institute to develop multi-valent vaccines for livestock [15] - Illumina launched a new version of its flagship cancer research testing solution, TruSight Oncology 500, enhancing capabilities for comprehensive genomic profiling [16] - Siemens Healthineers and Prisma Health deepened their partnership to improve cancer care in South Carolina and Tennessee, with Prisma investing $50 million [17]